UR-3216, a prodrug, is a novel, selective, and orally bioavailable platelet surface glycoprotein (GPIIb/IIIa) receptor antagonist. UR-3216 is the very tight binding of its active metabolite to platelets (Ki for resting platelets is < 1 nM). UR-2992, the active form of UR-3216, binds to platelets for a long period of time, while the unbound drug is rapidly cleared. UR-3216 is a promising, orally bioavailable GPIIb/IIIa antagonist for the treatment of cardiovascular diseases. References: Aga Y, Baba K, Tam S, Nakanishi T, Yoneda K, Kita J, Ueno H. UR-3216: a new generation oral platelet GPIIb/IIIa antagonist. Curr Pharm Des. 2004;10(14):1597-601. Review. PubMed PMID: 15134558.

纯度：≥98%

CAS：220386-65-2